证券代码：300358 证券简称：楚天科技 公告编号：2025-040 号 二、审议通过《关于选举公司第六届董事会专门委员会委员的议案》 根据《上市公司治理准则》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律 法规、规范性文件及《公司章程》等相关规定，公司董事会下设审计委员会、提 名委员会、薪酬与考核委员会、战略委员会四个专门委员会。 会议选举出的公司第六届董事会专门委员会人员组成情况如下： 审计委员会：独立董事张少球先生（召集人）、独立董事王善平先生、职工 代表董事李浪女士。 债券代码：123240 债券简称：楚天转债 楚天科技股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）第六届董事会第一次会议于 2025 年 5 月 29 日在公司会议室召开。会议通知于 2025 年 5 月 29 日现场送达给全体 董事。本次会议由公司董事长唐岳先生召集，应出席董事 14 人，实际出席董事 14 人，公司非董事 ...

Group 1: Company Overview - Chutian Technology Co., Ltd. is a well-known supplier of intelligent pharmaceutical equipment and overall technical solutions, focusing on various fields including chemical drugs, raw materials, biological drugs, and traditional Chinese medicine [2] - The company has expanded into the medical beauty and cosmetics sectors as part of its development strategy [2] Group 2: Financial Performance - The company aims to achieve profitability in 2025 after a loss in the first quarter, with expectations to turn around by mid-year or the third quarter through improved operational efficiency [2] - In 2024, Romaco Group reported a revenue of €208.75 million, a 1.26% increase year-on-year, but a net profit decline of 91.08% [4] Group 3: Order and Revenue Recognition - Domestic main engine orders are recognized upon obtaining customer-signed installation acceptance certificates, while international orders are recognized upon obtaining customs declarations and bills of lading [3] - The manufacturing cycle for main products typically ranges from 3 to 9 months, with delivery influenced by customer site conditions and project progress [2] Group 4: Impact of Tariffs - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. account for a very small portion of overall revenue [3] - The company has reduced reliance on direct imports from the U.S. by developing core components in-house and utilizing domestic or alternative imported brands [3] Group 5: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international competitiveness [5] - In 2024, domestic exports exceeded 1.2 billion, with products entering high-end markets in Europe [6] Group 6: New Products and Business Development - The company has made significant progress in the fields of peptides, medical beauty, and blood products, establishing a smart factory for beauty products [6] - Chutian Technology has set up a joint venture in peptide synthesis, with total assets of approximately ¥15.61 million and a net loss of ¥2.22 million in 2024 [6]

Group 1: Financial Performance and Goals - The company aims to achieve profitability by the second or third quarter of 2025, following a loss in the first quarter [2] - The target for the year is to turn losses into profits through improved operational efficiency and quality [2] Group 2: Order and Revenue Recognition - The typical manufacturing cycle for products ranges from 3 to 9 months, with revenue recognized upon customer acceptance of installation [2] - Domestic orders are confirmed based on the customer's signed acceptance of the installation [2] Group 3: Impact of Tariffs and Supply Chain - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. constitute a small portion of overall revenue [3] - The company has a low dependency on direct imports from the U.S. and has developed self-sufficiency for core components [3] Group 4: International Business Development - In 2024, the company’s export orders exceeded 1 billion RMB for the first time, with significant growth in international markets [3] - The company has established sales service centers in over ten countries to enhance international business [3][4] Group 5: New Products and Business Expansion - The company has expanded its business into new sectors such as peptides, medical beauty, and blood products, achieving notable success [4] - The subsidiary, Chutian Huaton, has diversified its product offerings into emerging fields like wastewater treatment and new energy lithium batteries [4]

Group 1: Industry Trends - The global pharmaceutical equipment market has surpassed $50 billion in 2024 and is expected to exceed $80 billion by 2030, with a compound annual growth rate (CAGR) of approximately 6-8% [1] - The "14th Five-Year" Pharmaceutical Industry Development Plan supports the development of high-end pharmaceutical equipment, with "domestic substitution" becoming a market trend [1] - The demand for equipment is rapidly increasing due to the transformation and upgrading of the pharmaceutical industry, driven by the rise of innovative drugs, biopharmaceuticals, and personalized formulations [2] Group 2: Technological Advancements - The construction of smart pharmaceutical factories is accelerating, with the adoption of MES systems, SCADA systems, and intelligent robots [2] - Data traceability has become a core element of GMP compliance, necessitating automated recording, audit trails, and electronic signatures [2] - The National Medical Products Administration's draft for the revised Good Manufacturing Practice (GMP) for sterile drugs aims to enhance the quality of sterile drug production in China [2] Group 3: Market Dynamics - There is a rising demand for personalized, small-batch, and multi-variety production, particularly for oncology drugs and rare disease medications [2] - Chinese pharmaceutical equipment companies are increasingly achieving international quality standards, enabling them to compete with top global firms [3] - The Asia-Pacific region, especially China and India, along with Latin America and the Middle East, is becoming a new growth driver for the global pharmaceutical equipment market [3] Group 4: Company Performance and Strategy - The increase in contract liabilities is attributed to a rise in orders and corresponding prepayments, without significant changes to the company's credit policy [3] - The company aims to enhance its international market presence and improve the quality of domestic contracts to drive business growth [3] - The company is focused on cost reduction and efficiency improvement through product optimization, supply chain cost management, and enhanced production efficiency [3] Group 5: Financial Overview - As of December 31, 2024, Chutian Microbead reported total assets of ¥81,528,093.58, net assets of ¥44,136,789.35, revenue of ¥14,738,069.68, and net profit of ¥635,992.39 [4] - Chutian Siwei Kang reported total assets of ¥24,429,337.66, net assets of ¥18,291,639.27, revenue of ¥9,688,180.16, and net profit of ¥5,529,069.30 as of December 31, 2024 [4] - Chutian Siyoute reported total assets of ¥32,086,926.74, net assets of -¥38,928,231.79, revenue of ¥7,933,943.61, and a net loss of -¥22,328,736.00 as of December 31, 2024 [4]

Group 1 - The core viewpoint of the news is that Chutian Technology's stock has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [1] - As of May 6, Chutian Technology's stock closed at 7.63 yuan, up 2.28%, with a latest price-to-book ratio of 1.08, marking a new low in 20 days and a total market capitalization of 4.504 billion yuan [1] - The company has seen a net outflow of main funds amounting to 1.4716 million yuan on May 6, with a total outflow of 13.0364 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - Chutian Technology Co., Ltd. specializes in the research, design, production, sales, and service of pharmaceutical equipment, becoming a leading enterprise in the domestic pharmaceutical equipment industry and a well-known player globally [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.083 billion yuan, a year-on-year decrease of 22.19%, and a net profit of -8.5569 million yuan, a year-on-year decline of 59.00%, with a sales gross margin of 29.76% [1] - In comparison to industry averages, Chutian Technology's price-to-earnings ratio (TTM) is -10.23, while the industry average is 48.90, indicating a significant underperformance relative to peers [2]

Financial Performance - In 2024, the company achieved a revenue of 5.83 billion yuan, a decrease of 14.94% compared to the previous year, with a net profit loss of 493 million yuan [1] - In Q1 2025, the company reported nearly 1.1 billion yuan in revenue, a year-on-year decline of 22%, but the net profit loss narrowed due to cost reduction measures implemented since August 2024 [1][2] Operational Adjustments - Since the second half of 2024, the company has implemented various improvement measures, including cost control, efficiency enhancement, and adjustments in marketing strategies, shifting focus from scale to a balance of scale and quality [2] - The company aims to continue these cost-reduction and efficiency-enhancement measures in 2025 while increasing efforts in international market expansion [2] Order and Profitability Outlook - New orders in 2024 remained stable compared to 2023, with a significant increase in export orders but a slight decline in domestic orders [3] - The gross margin for new domestic orders was low in the first half of 2024 but improved in the second half due to strategic adjustments and cost reduction efforts [3] - The company targets to achieve profitability by mid to late 2025, with ongoing efforts to enhance operational efficiency [3] Market Impact and Strategy - The impact of U.S. tariffs on the company's sales is minimal, as exports to the U.S. constitute a small portion of overall revenue [4] - The company has invested in self-research for core components, reducing reliance on direct imports [5] - The European market has shown significant growth, with a focus on promoting competitive and high-quality products [5] Subsidiary Performance - Romaco Group reported a revenue of 208.75 million euros in 2024, a 1.26% increase year-on-year, but net profit decreased by 91.08% due to delivery efficiency issues and supply chain disruptions [5]

Financial Performance - The company reported a basic earnings per share of -0.7668 yuan for 2024, a decrease of 240.29% compared to 0.5466 yuan in 2023 [1] - Net profit for 2024 was -4.53 billion yuan, down 242.9% from 3.17 billion yuan in 2023 [1] - Operating revenue decreased by 14.93% to 58.3 billion yuan in 2024 from 68.53 billion yuan in 2023 [1] - The return on equity (ROE) fell to -10.17% in 2024, a decline of 242.64% from 7.13% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 27,621.73 million shares, accounting for 47.92% of the circulating shares, with a decrease of 1,434.52 million shares compared to the previous period [1] - The largest shareholder, Changsha Chutian Investment Group Co., Ltd., holds 22,470.66 million shares, representing 39.00% of the total shares, with an increase of 881.83 million shares [2] - Hunan Caixin Jingxin Investment Partnership (Limited Partnership) reduced its holdings by 653.33 million shares, now holding 1,581.60 million shares, which is 2.74% of the total [2] Dividend Distribution - The company has announced no dividend distribution or stock increase for the current period [3]

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-029 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）第五届董事会任期即将届满， 为保证董事会的正常运行，根据《中华人民共和国公司法》及《公司章程》的 有关规定，公司于 2025 年 4 月 26 日召开第五届董事会第三十四次会议，审议 通过了《关于董事会换届选举暨提名第六届董事会非独立董事候选人的议案》、 《关于董事会换届选举暨提名第六届董事会独立董事候选人的议案》。 根据《公司章程》的规定，公司第六届董事会由 14 名董事组成，其中非 独立董事 9 名（含职工代表董事 1 名），独立董事 5 名。 经公司董事会提名委员会进行资格审查，董事会同意提名唐岳先生、曾凡 云先生、阳文录先生、周飞跃先生、肖云红女士、刘桂林先生、邱永谋先生、 汤佩徽女士为公司第六届董事会非独立董事候选人；同意提名王善 ...

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-037 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开职 工代表大会，经与会职工代表讨论和表决，一致同意如下事项： 选举李浪女士为公司第六届董事会职工代表董事（简历详见附件）。李浪 女士将与公司 2024 年年度股东大会选举产生的 8 名非独立董事及 5 名独立董 事共同组成公司第六届董事会，任期自 2024 年年度股东大会通过之日起三年。 上述职工代表董事符合相关法律法规及《公司章程》有关董事任职的资格 和条件。本次选举不会导致公司董事会中兼任公司高级管理人员以及由职工代 表担任的董事人数总计超过公司董事总数的二分之一。 特此公告。 楚天科技股份有限公司董事会 2025 年 4 月 28 日 附件：职工代表董事简历 李浪：女，19 ...

楚天科技股份有限公司 独立董事提名人声明与承诺 提名人楚天科技股份有限公司董事会 现就提名 张早平 为楚 天科技股份有限公司第六届董事会独立董事候选人发表公开声明。 被提名人已书面同意出任楚天科技股份有限公司第六届董事会独立 董事候选人（参见该独立董事候选人声明）。本次提名是在充分了解 被提名人职业、学历、专业资格、详细的工作经历、全部兼职、有 无重大失信等不良记录等情况后作出的，本提名人认为被提名人符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董事候选人任职资格及独立性的要求，具体声明并 承诺如下事项： 一、被提名人已经通过楚天科技股份有限公司第五届董事会提 名委员会或者独立董事专门会议资格审查，提名人与被提名人不存 在利害关系或者其他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八 条等规定不得担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独 ...